louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06761352: Questionnaire About Risk Factors of Iron Deficiency Anemia in Pregnancy
Official title: Questionnaire About Risk Factors of Iron Deficiency Anemia in Pregnancy and How to Prevent it
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Iron Deficiency Anaemia
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2025-01-07
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women attending Assiut university hospital for antenatal care

Brief summary: Anemia in pregnancy,and especially iron deficiency anemia is both a long standing scholarly interest ,the aim of my research to summarise the risk factors of iron deficiency anemia in pregnancy, especially in Egypt as a less developed country,and suggest recommendations about how to prevent it


Eligibility criteria: Inclusion Criteria:

* Women aged 18 years or older with established iron deficiency anemia (HB less than 10)
* established intrauterine pregnancy
* women want to participate in the study

Exclusion Criteria:

* anemia due to other causes
* recent blood transfusion in the last 3 months
* women with threatened miscarriage
* women are known to have pathological blood loss (urinary bleeding or GIT bleeding) 5- history of haematological disorder 6- women used iron in the past 3 months

Primary outcomes:
measure: Risk factors of iron deficiency anemia in pregnancy
timeFrame: 1 Year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05317052: The Effect of Massage and Musıc Therapy on Birth Pain, Posttravmatic Comfort and Posttraumatic Development
Official title: From Non-Pharmacologıcal Methods Applied to Primipars in Travay; The Effect of Massage And Music Therapy on Birth Pain, Posttravmatic Comfort and Posttraumatic Development: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Labor Pain
Posttraumatic Growth
Lead sponsor: Amasya University
Sponsor class: OTHER
First posted: 2022-04-07
Enrollment: 105
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Birth pain is the most severe painful experience faced by primiparous people. Massage and music therapy reduce tension in the muscles and reduce the feeling of pain. Massage and music therapy will be applied to pregnant women. No intervention will be made to a group of pregnant women. Numerical Pain Assessment, Post Traumatic Development Scale and Birth Comfort Scale will be used in the research.

Detailed description: Birth pain is one of the most severe and difficult to control pains known. Non-pharmacological methods used to cope with labor pain are cheap and reliable. Massage and music therapy in the first stage of labor are non-pharmacological methods used to reduce labor pain. The purpose of this research; non-pharmacological methods applied to primiparous in labor; The aim of this study is to examine the effects of massage and music therapy on labor pain, postpartum comfort and posttraumatic development. A total of 114 primiparous pregnant women who had a normal delivery expectation and were in the active phase of labor (4-5 cm dilatation) were planned to be included in the study. Massage and music therapy will be applied to pregnant women. No intervention will be made to a group of pregnant women. Numerical Pain Assessment, Post Traumatic Development Scale and Birth Comfort Scale will be used in the research.

Eligibility criteria: Inclusion Criteria:

* Expectation of normal vaginal delivery
* Having a term pregnancy
* Being primiparous - Being in the active phase of labor (Cervical dilatation 4 cm)
* Single pregnancy
* Being in vertex presentation
* Uncomplicated prenatal process
* Volunteering to participate in the study
* Being pregnant without back pain

Exclusion Criteria:

* Pregnant women whose birth resulted in cesarean section due to failure of labor to progress during labor
* Pregnant women who did not undergo induction
* Pregnant women who underwent pharmacological intervention for labor pain

Primary outcomes:
measure: Visual Analog Scale (VAS) Score
timeFrame: In the labour (active and transition phase)
Secondary outcomes:
measure: Postpartum Comfort Scale
timeFrame: At the enf of the delivery (In the 24 th hours)
measure: Posttraumatic Growth Inventory
timeFrame: At the enf of the delivery (In the 24 th hours)
Other outcomes:
Locations:
city: Amasya
country: Turkey
facility: Amasya University
Study officials:
References:
Clinical trial NCT04995432: Non Contrast MRI in Lower Extremity
Official title: Non Contrast MRI in Lower Extremity: Role in Varicose Vein , Stasis Ulcer and Obstructive Venous Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Venous Insufficiency of Leg
Venous Leg Ulcer
Venous Occlusion
Contrast Media Reaction
Keywords: MRI, CVS
contrast
reflux
ablation
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2021-08-09
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: retrospective, patients with leg venous disease

Brief summary: We collected retrospectively the non contrast MRI in chia yi memorial hospital for different venous disease of lower extremity morphology and flow ananlysis were done.

Detailed description: Retrospective, analysis of the venous figure by TRANCE MRI no drug/contrast median usage no radiation toxicity the range from the pelvic to the toe

Eligibility criteria: Inclusion Criteria:

* possible venous disease no contraindication for mri

Exclusion Criteria:

* could not tolerate mri packemaker

Primary outcomes:
measure: image quality
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Chiayi City
country: Taiwan
facility: Yao-Kuang Huang
Study officials:
References:
Clinical trial NCT01390532: Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT
Official title: Left Ventricular Dyssynchrony: Rest/Stress 3D Blood-Pool Gated D-SPECT Quantification With a High-Speed Dedicated Cardiac Camera Before CRT
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Left Ventricular Dyssynchrony
Keywords: Left Ventricular Dyssynchrony
Gated blood-pool
D-SPECT
Pharmacological stress
NYHA III/IV
LVEF < 35 %
QRS > 120 ms
optimal medical treatment
cardiac resynchronization therapy
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
Collaborators: name: Centre Jean Perrin
First posted: 2011-07-11
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Cardiac Resynchronization Therapy (CRT) is an established treatment for patients with advanced heart failure and left ventricular dyssynchrony (LVD). Too many patients do not clinically improve with CRT. New LVD markers other than QRS duration are needed.

Study objective : feasibility assessment of rest and real-time stress 3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel) to quantify LVD.

Detailed description: Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR).

Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA).

Eligibility criteria: Inclusion Criteria:

Chronic heart failure with LVEF \< 35 %, QRS \> 120 ms, NYHA III/IV, optimal medical therapy for more than one month.

* Patient with stable hemodynamic for more than one month,
* More than 18-year old man or woman,
* Patient having given his free, inform and signed consent,
* Patient place setting by the social security system,

Exclusion Criteria:

* Psychiatric disorder
* Any contra-indication to Technetium,
* Any contra-indication to dobutamin or atropin
* Personal or family history of sudden death
* Previous severe ventricular arrhythmia
* Obstructive cardiomyopathy, severe aortic stenosis,
* Pulmonary hypertension,
* History of renal, lung, hepatic, cardiac transplantation,
* Pregnant or breast-feeding Woman,
* Patient who can not conform to the requirements of the protocol,
* Patient included in another medical study,

Primary outcomes:
measure: Left ventricular phase standard deviation.
Secondary outcomes:
measure: Left ventricular entropy
measure: Left ventricle ejection fraction
measure: Quality of life.
measure: 6-minutes walking test
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: CHU de CLERMONT-FERRAND
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Bernard CITRON
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00731432: Herbal Periodontal Patch (THPP) for Gingival Inflammation in Diabetics
Official title: The Effect Of A Transmucosal Herbal Periodontal Patch (THPP) on Gingival Inflammation in Diabetic Patients
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: Gingival Inflammation in Diabetic Patients
Keywords: gingivitis, diabetes mellitus, herbal, oral inflammation
Lead sponsor: Izun Pharma Ltd
Sponsor class: INDUSTRY
First posted: 2008-08-11
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Diabetes increases the incidence and severity of periodontal inflammation and disease, and periodontal disease causes an increase in the severity of diabetes by worsening glycemic control and increasing insulin resistance.The Transmucosal Herbal Periodontal Patch (THPP) is a transmucosal patch containing an herbal compound that has an anti-inflammatory effect on gingival tissue.The primary objective of this study is to determine the efficacy of the Transmucosal Herbal Periodontal Patch (THPP) compared with placebo patch (PP) in reducing gingival inflammation at the site of placement in diabetic patients. We also aim to determine if the THPP decreases gingival inflammation throughout the mouth and the safety of THPP compared with placebo patch when applied to the mucosa in the treatment of gingival inflammation in diabetic patients.


Eligibility criteria: Inclusion Criteria:

* Male and female patients between the ages of 18 and 85 years
* Patients must have a minimum of 3 posterior teeth in all quadrants
* A mean gingival index (GI) of \>1.5 on the posterior teeth
* Diagnosis of Diabetes type 1 or 2, adequately controlled by diet and/or medications, as determined by the patient's physician

Exclusion Criteria:

* Allergy to any herbal medications
* Pregnancy or lactation
* Periodontal treatment in the last three months

Primary outcomes:
measure: The primary endpoint of the study will be the comparison between THPP and PP in reducing the gingival index (GI) at the site of patch placement
timeFrame: 5 days
Secondary outcomes:
measure: frequency and severity of any adverse event
timeFrame: 5 days
measure: Beta-glucuronidase enzyme found in gingival crevicular fluid (GCF) of the tested sites. The GCF will be collected from the second most posterior tooth in all four quadrants.
timeFrame: 5 days
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Herzog Hospital
Study officials:
affiliation: Izun Pharma Limited
name: Oded Yaniv, DMD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06745232: New Stereophotogrammetry System to Capture Complete-arch Impression
Official title: The Use of a New Stereophotogrammetry System to Capture Intra-operative Complete-arch Impression
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Prosthetic Complication
Prosthesis Failure, Dental
Keywords: fixed prosthesis
stereophotogrammetry
immediate loading
Lead sponsor: University of Rome Tor Vergata
Sponsor class: OTHER
First posted: 2024-12-20
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients in need of complete arch rehabilitations with dental implants and fixed dental prosthesis

Brief summary: Patients in need of complete arch restorations will be treated with dynamic navigation system. Once the implants are positioned, a new system of stereophotogrammetry will record the implant positions to capture a precise impression to deliver a fixed screw retained interim prosthesis


Eligibility criteria: Inclusion Criteria:

1. Healthy patients aged ≥18 years
2. Full mouth bleeding and full mouth plaque index lower than or equal to 25%
3. Bone height for at least 10 mm long implants
4. Bone width of at least 5 mm and 6 mm for narrow (NP 3.75/3.5 mm) and regular (RP 4.3 mm) implants, respectively
5. Fresh extraction sockets with an intact buccal wall
6. At least 4 and 5 mm of bone beyond the root apex in the mandible and maxilla
7. Minimal insertion torque of 45 Ncm

Exclusion Criteria:

1. General medical (American Society of Anesthesiologists, ASA, class III or IV) and/or psychiatric contraindications
2. Pregnancy and/or breastfeeding
3. Any interfering medication such as steroid therapy or bisphosphonate therapy
4. Alcohol and/or drug abuse
5. Heavy smoking (\>10 cigarettes/day)
6. Radiation therapy to head or neck region within 5 years
7. Untreated periodontitis
8. Acute and chronic infections of the adjacent tissues or natural dentition
9. Severe maxillomandibular skeletal discrepancy
10. High and moderate parafunctional activity
11. Absence of opposite teeth

Primary outcomes:
measure: Prosthetic Success
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: PTV
state: RM
Study officials:
References:
Clinical trial NCT00875732: Choosing the Right Pacing Mode in Heart Failure - The CHOICE Trial
Official title: CHOosing the rIght paCing Mode in Heart failurE : Should Heart Failure Patients With Bradycardia Receive Biventricular Pacemakers Rather Than Conventional Pacemakers?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure
Keywords: Resynchronization
Device
Bradycardia
atrioventricular block
Cardiac Resynchronization
Lead sponsor: University of Dundee
Sponsor class: OTHER
Collaborators: name: Chest, Heart and Stroke Association Scotland
name: Abbott Medical Devices
First posted: 2009-04-03
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the study is to see if biventricular pacemakers offer any advantage over conventional pacemakers in patients with heart failure who require pacemakers. The endpoints will be the 6 minute walking distance along with markers of cardiovascular function.

The investigators' hypothesis is that biventricular pacing is preferable to conventional pacing in these heart failure patients.


Eligibility criteria: Inclusion Criteria:

1. Left ventricular systolic dysfunction.
2. Atrio-ventricular node disease.
3. Anticipated to be more than 40% paced, (including patients in permanent atrial fibrillation).
4. Ability to walk independently (walking aid permitted).

Exclusion Criteria:

1. Patients meeting criteria for CRT by current guidelines will be excluded.
2. Life expectancy less than12 months.
3. Inability to walk independently.
4. Patients not likely to be compliant with follow-up.
5. Bradyarrhythmia due with sino-atrial disease only.

Primary outcomes:
measure: 6 minute hall walk test
timeFrame: Baseline, 3, 6, 9 and 12 months
Secondary outcomes:
measure: Endothelial Function
timeFrame: Baseline, 3, 6, 9 and 12 months
measure: Cardiac Output
timeFrame: Baseline, 3, 6, 9 and 12 months
Other outcomes:
Locations:
city: Dundee
country: United Kingdom
facility: Ninewells Hospital & Medical School
state: UK
Study officials:
References:
Clinical trial NCT00240032: A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
Official title: A Double-Blind, Randomized, Placebo Controlled Study of An Oral Antihistamine on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® Using Autoject® 2 for Glass Syringe.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Multiple Sclerosis
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2005-10-17
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections. Patients will be assigned (like a flip of a coin) to take either a placebo or an antihistamine (Zyrtec®) prior to performing their daily Copaxone® injections. The patient and physician will be unaware whether they are taking a placebo or antihistamine during the study.


Eligibility criteria: Inclusion Criteria:

* Male or female
* 18 years of age or older
* Diagnosis of RRMS
* Beginning or recently (within \< 3months) began self-injecting Copaxone®

Exclusion Criteria:

* Taking any other immunomodulatory therapy in conjunction with Copaxone®
* Unable to perform subcutaneous self-injection
* Pregnant or trying to become pregnant, or breast feeding during the study
* Previously participated in this study or in another clinical trial in the past 30 days

Primary outcomes:
measure: Injection Site Reaction
timeFrame: 5 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Teva Neuroscience, Inc.
name: MerriKay Oleen-Burkey, Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06381232: Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population
Official title: Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: General Health
Wellness
Lead sponsor: Viome
Sponsor class: INDUSTRY
First posted: 2024-04-24
Enrollment: 20000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants with specific phenotypes of interest and matched healthy controls.

Brief summary: The purpose of the study is to collect and analyze physiological, physical, and molecular data from a diverse population to increase our understanding of how such parameters are associated with health and disease.

Detailed description: The analyses conducted by Viome will include, but are not limited to: genetic, transcriptomic, metabolomic, physiological, and physical. The samples collected from participants may include any of these: stool, blood, saliva, cheek swab, vaginal, breast milk/colostrum, nasal swabs or washes, and urine.

Study participants will collect the clinical samples and ship them to Viome labs or CROs (Contract Research Organizations), where they will be analyzed.

The objective of the study is to establish which foods correspond with increased wellness, and which foods correspond to decreased wellness.

The study hypothesis is that by monitoring the patterns of food intake and lifestyle parameters, in conjunction with non-invasive sample testing, personalized diet and lifestyle recommendations can be elucidated.

Eligibility criteria: Inclusion Criteria:

* Anyone that resides in the US at the time of enrollment.

Exclusion Criteria:

* None

Primary outcomes:
measure: Molecular Determinants of Health and Disease
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bothell
country: United States
facility: Viome Life Sciences
state: Washington
Study officials:
affiliation: Viome
name: Momchilo Vuyisich, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03399032: Pharmacokinetics of Caspofungin
Official title: Pharmacokinetics of Caspofungin in Critically Ill Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Septic Shock
Fungal Infection
Critical Illness
Keywords: caspofungin
pharmacokinetics
Lead sponsor: Medical University of Lublin
Sponsor class: OTHER
First posted: 2018-01-16
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to ICU due to severer sepsis recognition. Both medical and surgical patients will be included. Any site of infection will be treated in the manner.

Brief summary: The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.

Detailed description: This is a prospective observational study performed on critically ill patients. Inclusion criteria are: severe sepsis on admission requiring broad-spectrum antibiotics. Both medical and surgical patients will be included. Any type of infections will be included (pulmonary, abdominal, urinary tract, etc.) Antibiotics regimen includes: broad spectrum anti-bacterial antibiotics plus caspofungin (70 mg i.v. on the first day day, and 50 mg i.v. on the consecutive days, once daily.

Blood samples (3 mL) will be collected 2, 4, 8,12 and 24 hours after each dose of caspofungin for 3 consecutive days. The standard arterial canula will be used to obtain samples.

30 minutes after each sample collection, blood will be centrifuged for 10 minutes at 3,000 rpms. Subsequently, supernatant will be collected and frozen.

Serum caspofungin concentration will be measured with high performance liquid chromatography.

Each patient's hemodynamics parameters will be recorded with the use of transpulmonary thermodilution technique (PICCO). Other therapies i.e.: ventilatory support, sedation, an antifungal agent will be given as required.

Eligibility criteria: Inclusion Criteria:

* Patients who require ICU treatment due to severe sepsis age
* 18-80 years
* an eligible consent obtained from the patient or his/her attendant

Exclusion Criteria:

* allergy to caspofungin
* lack of consent to participate in the study
* age of patients below 18 or above 80 years

Primary outcomes:
measure: Serum concentration of caspofungin
timeFrame: 72 hours for each patient from the tigecycline treatment initiation
Secondary outcomes:
Other outcomes:
Locations:
city: Lublin
country: Poland
facility: II Department of Anesthesia and Intensive Care, Medical University of Lublin
Study officials:
References:
citation: Borsuk-De Moor A, Sysiak-Slawecka J, Rypulak E, Borys M, Piwowarczyk P, Raszewski G, Onichimowski D, Czuczwar M, Wiczling P. Nonstationary Pharmacokinetics of Caspofungin in ICU Patients. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00345-20. doi: 10.1128/AAC.00345-20. Print 2020 Aug 20.